Streetbeat News

Analyst Ratings

SHOP

Piper Sandler analyst Clarke Jeffries has reiterated an Underweight rating on Shopify (NYSE:SHOP) and maintained a price target of $56. This suggests that the analyst believes Shopify's stock may not perform well in the near future.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:49 am

ZETA

Needham analyst Ryan MacDonald has reiterated a Buy rating on Zeta Global Holdings (NYSE:ZETA) and maintained a $13 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:46 am

CLFD

Needham analyst Ryan Koontz has reiterated a Buy rating on Clearfield (NASDAQ:CLFD) and maintained a $40 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:44 am

CRNT

Needham analyst Alex Henderson has reiterated a Buy rating on Ceragon Networks (NASDAQ:CRNT) and maintained a price target of $5.25.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:42 am

KA

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Kineta (NASDAQ:KA) and maintained a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:40 am

DZSI

Needham analyst Ryan Koontz has reiterated a Buy rating on DZS Inc. (NASDAQ:DZSI) and maintained a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:26 am

KLTR

Needham analyst Ryan Koontz has reiterated a Buy rating on Kaltura (NASDAQ:KLTR) and maintained a price target of $5. The reaffirmation of the Buy rating suggests a positive outlook on Kaltura's stock by the analyst.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:24 am

HALO

HC Wainwright & Co. analyst Mitchell Kapoor has maintained a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) but reduced the price target from $61 to $48.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:22 am

IVVD

HC Wainwright & Co. analyst Patrick Trucchio has maintained a Buy rating on Invivyd (NASDAQ:IVVD) and increased the price target from $5 to $15.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:16 am

TARO

HC Wainwright & Co. analyst Raghuram Selvaraju has downgraded Taro Pharmaceutical Industries (NYSE:TARO) from Buy to Neutral while maintaining the price target at $43.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:15 am